Table 1.
Overview of the impact of JAK inhibitors on B cell immune responses based on pharmacokinetic, in vitro and in vivo studies.
| Description | JAK inhibitor | References |
|---|---|---|
| Increase in B cell numbers in peripheral blood | Tofacitinib, Baricitinib, Filgotinib | (163, 164, 204, 205, 214, 226) |
| Suppression of B cell activation, differentiation and class-switching | Tofacitinib, Baricitinib, Filgotinib | (202, 207, 215, 216, 227) |
| Impairment of plasmablast development and immunoglobulin secretion | Tofacitinib, Baricitinib | (208, 215, 216) |
| Inhibition of antibody production | Tofacitinib, Filgotinib | (200, 208–210, 227) |
| Inhibition of cytokine production relevant for B cell activation and survival | Tofacitinib, Baricitinib, Upadacitinib, Filgotinib | (215, 216, 218, 220, 227) |
| Downregulation of the antigen presenting cell function of B cells | Baricitinib | (217) |
| Reduction of T helper cell responses | Baricitinib | (215, 217) |
| Inhibition of STAT phosphorylation on B cells | Tofacitinib, Baricitinib, Upadacitinib, Filgotinib | (219) |
| Downregulation of B-cell chemoattractant, activation, survival and differentiation biomarkers | Filgotinib | (226) |
| Decrease in B cell lymphoid infiltrates in tissues | Filgotinib | (227) |